

Practical Gynecology, 2nd Edition – Chapter 18 References

1. **ACS Cancer Facts and Figures.** 2007, www.cancer.org, accessed October 27, 2007.

*2. **Berry DA, Cronin KA, Plevritis SK, et al.** Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med.* 2005;353:1784-92. *A consortium of investigators describe and compare the results of seven different statistical models developed to assess the relative and absolute contributions of screening mammography and adjuvant treatment to reductions of U.S. breast cancer mortality from 1975 to 2000.*

3. **Malone KE, Daling JR, Thompson JD, et al.** BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first degree family history. *JAMA.* 1998;279:922-9.

4. **Ford D, Easton DF, Stratton M, et al.** Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. *Am J Hum Genet.* 1998;62:676-89.

5. **Fletcher SW, Black W, Harris R, et al.** Report of the International Workshop on Screening for Breast Cancer. *J Natl Cancer Inst.* 1993;85:1644.

6. **Humphrey LL, Helfand M, Chan BK, et al.** Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;137:347-60.

7. **ACS guidelines for the early detection of breast cancer: update 1997.** *CA Cancer J Clin.* 1997;47:150-3.

8. **American College of Obstetricians and Gynecologists.** Primary and preventive care: periodic assessments. ACOG Committee Opinion 246. Washington, DC: ACOG, 2000.

*9. **U.S. Preventive Services Task Force, Recommendations and Rationale: Screening for Breast Cancer,** found at <http://www.ahrq.gov/clinic/3rduspstf/breastcancer/brcanrr.htm> (Accessed August 31, 2007). *A comprehensive review of the evidence behind current U.S. Preventive Services Task Force recommendations for breast cancer screening.*

10. **Ferrini R, Mannino E, Ramsdell E, Hill L.** Screening mammography for breast cancer: American College of Preventive Medicine practice policy statement. *Am J Prev Med* 1996;12:340-1.

11. **Canadian Task Force on the Periodic Health Examination.** Ottawa (Canada): Health Canada; 1994:788-795 (reaffirmed by the Canadian Task Force on the Periodic Health Examination 1999). Available at: <http://www.ctfphc.org/index.html>. Accessed August 31, 2007.

12. **Canadian Task Force on Preventive Health Care.** Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer. Available at: <http://www.ctfphc.org>. Accessed August 31, 2007.
13. **Baxter N and the Canadian Task Force on Preventive Health Care.** Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? *CMAJ*. 2001;164:1837-46.
14. **Lewin JM, D’Orsi CJ, Hendrick RE, et al.** Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. *Am J Roentgenol*. 2002;179:671.
15. **Skaane P, Young K, and Skjennald A.** Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading--Oslo I study. *Radiology*. 2003;229:877.
16. **Skaane P and Skjennald A.** Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program--the Oslo II Study. *Radiology*. 2004;232:197.
- *17. **Pisano ED, Gatsonis C, Hendrick E, et al.** Diagnostic performance of digital versus film mammography for breast-cancer screening. *N Engl J Med*. 2005;353:1773.
- *18. **Lord SJ, Lei W, Craft P, et al.** A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. *Eur J Cancer*. 2007;43:1905-1917.
19. **Houssami N and Wilson R.** Should women at high risk of breast cancer have screening magnetic resonance imaging (MRI)? *Breast*. 2007;16:2-4.
20. **Port ER, Park A, Borgen PI, et al.** Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. *Ann Surg Oncol*. 2007;14:1051-7.
21. **Liberman L.** Breast cancer screening with MRI--What are the data for patients at high risk? *N Engl J Med*. 351;5:497-500.
22. **Smart CR, Hartmann WH, Beahrs OH, et al.** Insights into breast cancer screening of young women: the Breast Cancer Detection Demonstration Project. *Cancer*. 1993;72:1449.
- *23. **Bobo JK, Lee NC, Thames SF.** Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. *J Natl Cancer Inst*. 2000;92:971-6.
- *24. **Ganschow PS, Norlock FE, Jacobs EA, Marcus EA (Eds.),** *Breast Health and Common Breast Problems: A Practical Approach, ACP Women’s Health Series, American College of Physicians, 2004. An excellent reference for the primary care provider for the assessment and management of common breast problems, this book covers many of the same topics as this chapter but in greater detail, and includes*

discussion of other topics such as breastfeeding and lactation, gynecomastia, and helping patients decide about augmentation and reduction mammoplasty procedures.

25. **Henderson IC.** Risk factors for breast cancer development. *Cancer.* 1993;71(suppl):2127-40.
26. **Aisenberg A, Finkelstein D, Doppke K, et al.** High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. *Cancer.* 1997;79:1203-9.
27. **Bhatia S, Robison L, Oberlin O, et al.** Breast cancer and other second neoplasms after childhood Hodgkin's disease. *N Engl J Med.* 1996;334:745-50.
28. **Dupont WD, Page DL, Park FF.** Long-term risk for breast cancer in women with fibroadenoma. *N Engl J Med.* 1994;331:10-15.
29. **Smith-Warner SA, Spiegelman D, Yuan S-S, et al.** Alcohol and breast cancer in women: a pooled analysis of cohort studies. *JAMA.* 1998;279:535-40.
30. **Huang Z, Hankinson SE, Colditz GA, et al.** Dual effects of weight and weight gain on breast cancer risk. *JAMA.* 1997;278:1407-11, 1448-9.
31. **Thune I, Brenn T, Lund E, et al.** Physical activity and the risk of breast cancer. *N Engl J Med.* 1997;336:1269-74.
32. **Thomas HV, Reeves GK, Key TJ.** Endogenous estrogen and postmenopausal breast cancer: a quantitative review. *Cancer Causes Control.* 1997;8:922-8.
33. **Zhang Y, Kiel DP, Kreger BE, et al.** Bone mass and the risk of breast cancer among postmenopausal women. *N Engl J Med.* 1997;336:611-7.
- *34. **McCormack VA and dos Santos Silva I.** Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2006;15:1159-69.
- *35. **Tamimi RM et al.** Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. *J Natl Cancer Inst.* 2007;99:1178-87.
- *36. **U.S. Preventive Services Task Force.** Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. *Ann Intern Med.* 2005;143:355.
37. **National Cancer Institute.**
<http://cancercontrol.cancer.gov/ocs/prevalence/prevalence.html>, accessed October 3, 2007.
- *38. **Hewitt M, Greenfield S, Stovall E (Eds).** **From cancer patient to cancer survivor: lost in transition.** Washington, DC: National Academies Press, 2006.

*39. **Grunefeld E, Levine MN, Julian JA, et al.** Randomized trial of long-term follow-up for early stage breast cancer: a comparison of family physician vs. specialist care. *J Clin Oncol.* 2006;24:848-54. *This multi-center trial involved 968 patients who had completed successful adjuvant treatment for early stage breast cancer and who were between 9 and 15 months from the time of their diagnosis at study enrolment. They were randomized to follow up care at either a cancer center or with their family physician (with recommendations for follow-up in the form of a one-page guideline). After 2 to 6 years of follow-up, no difference was detected in either the recurrence of serious clinical events or in health-related quality of life.*

40. **Nissen MJ, Beran MS, Lee MW, et al.** Views of primary care providers on follow-up care of cancer patients, *Fam Med.* 2007;39:477-82.

41. **Khatcheressian JL, Wolff AC, Smith TJ et al.** American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. *J Clin Oncol.* 2006;24:5091-7.

42. **Harris L, Fritsche H, Mennel R et al.** The American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. *J Clin Oncol.* 2007. **AUTHOR, PLEASE PROVIDE PAGE NUMBERS.**

*43. **Rojas MP, Telaro E, Russo A, et al.** Follow-up strategies for women treated for early breast cancer. *Cochrane Database Syst Rev.* 2005: CD001768. *This study pooled data from four randomized controlled trials involving 3,055 women with stage I, II, or III breast cancer compared follow-up programs based on regular physical examinations and mammography alone with more intensive programs involving routine lab and imaging tests. It found the former strategy was just as effective in the timeliness of detecting recurrence, in overall survival, and in quality-of-life.*

44. **Impact of follow-up testing on survival and health-related quality of life in breast cancer patients.** A multi-center randomized controlled trial. The GIVIO Investigators. *JAMA.* 1994;271:1587-92.

45. **Rosselli Del Turco M, Palli D, Cariddi A, et al.** Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. *JAMA.* 1994;271:1593-7.

46. **de Bock GH, Bonnema J, van der Hage J, et al.** Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. *J Clin Oncol.* 2004;22:4010-8.

47. **Palli D, Russo A, Saieva C, et al.** Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. *JAMA.* 1999;281:1586.

*48. **Barton MB, Harris R, Fletcher SW.** Does this patient have breast cancer? The screening clinical breast examination: should it be done? how? *JAMA.* 1999;282:1270-80. *From the Rational Clinical Exam Series of JAMA, this is an outstanding review of the*

evidence on the effectiveness of the clinical breast examination (CBE) in screening for breast cancer and on the best technique for exam performance. Authors conclude that although screening CBE alone does not rule out breast cancer, the high specificity of selected abnormal findings greatly increases the likelihood of breast cancer. Overall, they estimated CBE sensitivity to be 54% and specificity 94%.

49. **Baines CJ, Miller AB, and Bassett AA.** Physical examination: Its role as a single screening modality in the Canadian National Breast Screening Study. *Cancer.* 1989;63:1816-1822.

*50. **Barton MB, Elmore JG, Fletcher SW.** Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation and outcome. *Ann Int Med.* 1999;130:651-57. *This retrospective cohort study of 2400 women aged 40 to 69 from 1983 to 1993 looked at frequency of presentation with breast symptoms, the evaluation of those symptoms, and the frequency of cancer diagnosis by type of symptom. The investigators found that 16 percent of women with breast symptoms during the 10-year period. Sixty-six percent of breast symptoms were evaluated beyond the initial clinical encounter. Cancer was ultimately diagnosed in 4.5% of episodes overall; in 1.2% of episodes involving complaint of breast pain only; in 10.7% of those involving breast mass only; in 2.0% of those involving nipple discharge only; and in 4.0% of those involving breast lumpiness as the sole presenting complaint.*

51. **Kerlikowske K, Grady D, Barclay J, et al.** Likelihood ratios for modern screening mammography. *JAMA.* 1996;276:39-43.

52. **Mahoney L and Csima A.** Efficiency of palpation in clinical detection of breast cancer. *CMAJ.* 1982;127:729-730.

53. **Venet L, Strax P, Venet W, et al.** Adequacies and inadequacies of breast examinations by physicians in mass screening. *Cancer.* 1971;28:1546-1551.

*54. **Hindle WH, Davis L, Wright D.** Clinical value of mammography for symptomatic women 35 years of age and younger. *Am J Obstet Gynecol.* 1999;180:1484-90.

55. **Cady B, et al.** Evaluation of common breast problems: guidance for primary care providers. *Cancer.* 1998;48:49-63.

*56. **Barlow WE, Lehman CD, Zheng Y, et al.** Performance of diagnostic mammography for women with signs or symptoms of breast cancer. *J Natl Cancer Inst.* 2002;94:1151-9.

57. **Huynh PT, Jarolimek AM, Daye S.** The false negative mammogram. *Radiographics.* 1998;18:1137-54.

58. **Lee, AH.** Why is carcinoma of the breast more frequent in the upper outer quadrant? A case series based on needle core biopsy diagnoses. *Breast.* 2005;14:151-152.

59. **Lieberman L, Abramson AF, Squires FB, et al.** The Breast Imaging Reporting and Data System: positive predictive value of mammographic features and final assessment categories. *AJR*. 1998;171:35-40.
60. **Hanchak NA, Kessler HB, MacPherson S, et al.** Screening mammography: experience in a health maintenance organization. *Radiology*. 1997;205:441-445.
61. **Nguyen M, McCombs MM, Ghandehari S, et al.** An update on core needle biopsy for radiographically detected lesions. *Cancer*. 1996;78:2340-2345.
- *62. **Lacquement MA, Mitchell D, Hollingsworth AB.** Positive predictive value of the Breast Imaging Reporting and Data System. *J Am Coll Surg*. 1999;189:34-40.
63. **Bazzocchi M, Zuiani C, Panizza P, et al.** Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. *AJR Am J Roentgenol*. 2006;186:1723-32.
- *64. **Karliner LS, Patricia Kaplan C, Juarbe T, et al.** Poor patient comprehension of abnormal mammography results. *J Gen Int Med*. 2005;20:432-437. *This survey of 970 women age 40 to 80 years from 4 clinical sites who had had an abnormal mammogram found that almost half of the women did not understand that their mammogram was abnormal. Women notified by their clinician of abnormal findings in person or by telephone were more likely than those notified in writing to understand their result was abnormal.*
- *65. **Elmore JG, Barton MB, Mocerri VM et al.** Ten-year risk of false positive screening mammograms and clinical breast examinations. *N Engl J Med*. 1998;338:1089-96.
66. **Rosner D, Baird D.** What ultrasonography can tell in breast masses that mammography and physical examination cannot. *J Surg Oncol*. 1985;28:308-13.
67. **Sickles EA, Filly RA, Callen PW.** Benign breast lesions: ultrasound detection and diagnosis. *Radiology*. 1984;151:467-70.
- *68. **Hindle WH, Arias RD, Florentine B, et al.** Lack of utility in clinical practice of cytologic examination of nonbloody cyst fluid from palpable breast cysts. *Am J Obstet Gynecol*. 2000;182:1300-5.
69. **Leis HP Jr.** Gross breast cysts: significance and management. *Contemp Surg*. 1991;39:13-20.
70. **Hamed H, et al.** Follow-up of patients with aspirated breast cysts is necessary. *Arch Surg*. 1989;124:253-5.
71. **Hughes LE, Bundred NJ.** Breast macrocysts. *World J Surg*. 1989;13:711-4.
72. **Boyd NF, et al.** Prospective evaluation of physical examination of the breast. *Am J Surg*. 1981;142:331-4.

73. **Layfield LJ, Glasgow BJ, Cramer H.** Fine-needle aspiration in the management of breast masses. *Pathol Annu.* 1989;24:23-62.
74. **Hammond S, et al.** Statistical analysis of fine-needle aspiration cytology of the breast: a review of 678 cases plus 4265 cases from the literature. *Acta Cytol.* 1987;31:276-80.
75. **Love SM, Gelman RS, Silen W.** Fibrocystic “disease” of the breast – a nondisease? *N Engl J Med.* 1982;307:1010-4.
- *76. **Santen RJ and Mansel R.** Current concepts: benign breast disorders. *N Engl J Med.* 2005;353:275-85. *An excellent review of the classification, clinical features, evaluation, and treatment of a spectrum of benign breast disorders, with an emphasis on a rational diagnostic approach for the exclusion of malignancy.*
- *77. **Woo JC, Yu T, Hurd TC.** Breast cancer in pregnancy: a literature review. *Arch Surg.* 2003;138:91–99.
78. **Nicklas A and Baker M.** Imaging strategies in pregnant cancer patients. *Semin Oncol.* 2000;27:623-632.
- *79. **Duijm LEM, Fuit GL, Hendriks JHCL, et al.** Value of breast imaging in women with painful breasts: observational follow-up study. *BMJ.* 1998;317:1492-5.
- *80. **Smith RL, Pruthi S, Fitzpatrick LA.** Evaluation and management of breast pain. *Mayo Clin Proc.* 2004;79:353-372. *A comprehensive review of the clinical features, etiologies, evaluation, and management of cyclic and noncyclic mastalgia.*
81. **Horner NK and Lampe JW.** Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. *J Am Diet Assoc.* 200;100:1368-1380.
82. **Blommers J, de Lange-de-Klerk ESM, Kuik DJ, et al.** Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. *Am J Obstet Gynecol.* 2002;187:1389-94.
83. **Peters F, Diemer P, Mecks O, et al.** Severity of mastalgia in relation to milk duct dilatation. *Obstet Gynecol.* 2003;101:54-60.
84. **Kollias J, Sibbering DM, Blamey RW.** Topical nonsteroidal anti-inflammatory gel for diffuse chest wall pain in mastalgia patients. In: Mansel RE, ed. *Recent developments in the study of benign breast disease.* London: Parthenon Publishing, 1997:119-24.
85. **Petrakis NL.** Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. *Breast Cancer Res Treat.* 1986;8:7-19.
86. **Takeda T, et al.** Cytologic studies of nipple discharge. *Acta Cytol.* 1982;26:35.
-

87. **Chaudary M, et al.** Nipple discharge: the diagnostic value of testing for occult blood. *Am J Surg.* 1982;196:651.
88. **Devitt JE.** Management of nipple discharge by clinical findings. *Am J Surg.* 1985;149:789-92.
89. **Brook I.** Microbiology of nonpuerperal breast abscesses. *J Infect Dis.* 1988;157:377-9.
- *90. **Berens, PD.** Prenatal, intrapartum, and postpartum support of the lactating mother. *Pediatr Clin North Am.* 2001; 48:365-75.
91. **Lawrence RA, Lawrence RM.** Management of the mother-infant nursing couple. In: *Breastfeeding: A Guide for the Medical Profession*, 5th ed. St. Louis: CV Mosby; 1999:233-95.